SI3197883T1 - Nove spojine - Google Patents

Nove spojine

Info

Publication number
SI3197883T1
SI3197883T1 SI201531254T SI201531254T SI3197883T1 SI 3197883 T1 SI3197883 T1 SI 3197883T1 SI 201531254 T SI201531254 T SI 201531254T SI 201531254 T SI201531254 T SI 201531254T SI 3197883 T1 SI3197883 T1 SI 3197883T1
Authority
SI
Slovenia
Prior art keywords
novel compounds
novel
compounds
Prior art date
Application number
SI201531254T
Other languages
English (en)
Slovenian (sl)
Inventor
Alison Jones
Mark Ian Kemp
Martin Lee Stockley
Karl Richard Gibson
Gavin Alistair Whitlock
Andrew Madin
Original Assignee
Mission Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Limited filed Critical Mission Therapeutics Limited
Publication of SI3197883T1 publication Critical patent/SI3197883T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201531254T 2014-09-23 2015-09-22 Nove spojine SI3197883T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1416754.8A GB201416754D0 (en) 2014-09-23 2014-09-23 Novel compounds
EP15774652.0A EP3197883B1 (en) 2014-09-23 2015-09-22 Novel compounds
PCT/GB2015/052729 WO2016046530A1 (en) 2014-09-23 2015-09-22 Novel compounds

Publications (1)

Publication Number Publication Date
SI3197883T1 true SI3197883T1 (sl) 2020-08-31

Family

ID=51869322

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531254T SI3197883T1 (sl) 2014-09-23 2015-09-22 Nove spojine

Country Status (24)

Country Link
US (5) US9926307B2 (enExample)
EP (2) EP3828179A1 (enExample)
JP (3) JP6549703B2 (enExample)
KR (1) KR102493967B1 (enExample)
CN (2) CN107001339B (enExample)
AU (1) AU2015323572B2 (enExample)
CA (1) CA2958262C (enExample)
CY (1) CY1122983T1 (enExample)
DK (1) DK3197883T3 (enExample)
ES (1) ES2798473T3 (enExample)
GB (1) GB201416754D0 (enExample)
HR (1) HRP20200962T1 (enExample)
HU (1) HUE050732T2 (enExample)
IL (1) IL250345B (enExample)
LT (1) LT3197883T (enExample)
MX (1) MX2017003358A (enExample)
PL (1) PL3197883T3 (enExample)
PT (1) PT3197883T (enExample)
RS (1) RS60468B1 (enExample)
RU (1) RU2691389C2 (enExample)
SG (1) SG11201700847YA (enExample)
SI (1) SI3197883T1 (enExample)
SM (1) SMT202000323T1 (enExample)
WO (1) WO2016046530A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3157916B1 (en) 2014-06-19 2018-12-12 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
MD3277677T2 (ro) * 2015-03-30 2021-07-31 Mission Therapeutics Ltd Compuși de 1-ciano-pirolidină utilizați ca inhibitori de USP30
CA2990583A1 (en) * 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
WO2017009650A1 (en) * 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) * 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) * 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
CN108884068B (zh) 2016-03-24 2021-02-26 特殊治疗有限公司 作为dub抑制剂的1-氰基-吡咯烷衍生物
WO2017184751A1 (en) * 2016-04-20 2017-10-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing hypertension
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
JP6959332B2 (ja) * 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
WO2018148863A1 (zh) * 2017-02-14 2018-08-23 华东理工大学 N-(5-吗啉代噻唑-2-基)甲酰胺类化合物及其制备方法和用途
JP7079794B2 (ja) * 2017-05-10 2022-06-02 コーテクシーミー， インコーポレイテッド アミノピリジン化合物ならびにその調製および使用のための方法
GB201708652D0 (en) * 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
CN110831936B (zh) * 2017-06-20 2023-03-28 特殊治疗有限公司 具有dub抑制剂活性的取代氰基吡咯烷
EP3661941B1 (en) * 2017-08-01 2022-12-14 Merck Patent GmbH Thiazolopyridine derivatives as adenosine receptor antagonists
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
ES2950757T3 (es) * 2017-10-06 2023-10-13 Forma Therapeutics Inc Inhibición de la peptidasa específica de la ubiquitina 30
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US10653688B2 (en) 2017-10-27 2020-05-19 Samumed, Llc 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
WO2019089835A1 (en) 2017-10-31 2019-05-09 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
AR114422A1 (es) 2018-03-30 2020-09-02 Syngenta Participations Ag Compuestos herbicidas
BR112020023107A2 (pt) 2018-05-14 2021-02-02 Ariad Pharmaceuticals, Inc. sais farmacêuticos de derivados de pirimidina e método de tratamento de distúrbios
BR112020021921A2 (pt) 2018-05-17 2021-01-26 Forma Therapeutics, Inc. compostos bicíclicos fundidos úteis como inibidores de peptidase 30 específica de ubiquitina
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
JP2021534122A (ja) 2018-08-09 2021-12-09 ヴァロ アーリー ディスカバリー， インコーポレイテッド 脱ユビキチン化酵素ｕｓｐ２５及びｕｓｐ２８の阻害
US11572374B2 (en) 2018-08-14 2023-02-07 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
AR117189A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
AR116948A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
WO2020256432A1 (ko) * 2019-06-19 2020-12-24 주식회사 엘지화학 인돌 또는 인다졸 화합물의 제조방법
GB201912674D0 (en) * 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
CN114845709B (zh) * 2019-11-05 2024-10-01 德米拉公司 用于治疗炎性病症的mrgprx2拮抗剂
KR20230006487A (ko) 2020-04-08 2023-01-10 미션 테라퓨틱스 엘티디 Usp30 억제제로서의 활성을 갖는 n-시아노피롤리딘
US20230234967A1 (en) * 2020-05-28 2023-07-27 Senda Biosciences, Inc. Fused Azole Heterocycles as AHR Antagonists
MX2022014429A (es) * 2020-05-28 2022-12-07 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de usp30.
US20230303547A1 (en) * 2020-06-04 2023-09-28 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
HUE072598T2 (hu) 2020-06-08 2025-11-28 Mission Therapeutics Ltd 1-(5-(2-cianopiridin-4-il)oxazol-2-karbonil)-4-metilhexahidropirrolo[3,4-B]pirrol-5(1H)-karbonitril felhasználásra, mint USP30 inhibitor, mitokondriális diszfunkció, rák és fibrózisok kezelésében
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
TW202402754A (zh) 2021-03-04 2024-01-16 美商美國禮來大藥廠 Fgfr3抑制劑化合物
AU2022317661A1 (en) * 2021-07-26 2024-01-18 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
EP4441044A1 (en) 2021-12-01 2024-10-09 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
KR20240133695A (ko) * 2021-12-10 2024-09-04 프로테나 바이오사이언시즈 리미티드 Dyrk1a 억제제로서의 헤테로시클릭 화합물
WO2024259121A1 (en) * 2023-06-14 2024-12-19 Prothena Biosciences Limited Bicyclic heteroaromatic compounds for treating neurological disorders
CN119528901A (zh) * 2024-11-05 2025-02-28 上海市同济医院 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
NZ507760A (en) 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
EP1272467A4 (en) 2000-04-06 2003-05-07 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
JP2007529496A (ja) 2004-03-19 2007-10-25 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
WO2010052222A1 (en) 2008-11-07 2010-05-14 Evotec Neurosciences Gmbh (dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
EP2362775B1 (en) 2008-11-20 2015-08-05 GlaxoSmithKline LLC Chemical compounds
CN103261169A (zh) * 2010-09-24 2013-08-21 密歇根大学董事会 脱泛素酶抑制剂及其应用方法
WO2012174312A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
KR102022575B1 (ko) * 2011-10-19 2019-09-18 비보룩스 아베 탈유비퀴틴화 활성의 저해 방법
EP2874997A4 (en) 2012-07-19 2016-01-06 Univ Drexel NEW SIGMA RECEPTOR LIGANDS AND METHOD FOR REGULATING CELLULAR PROTEIN HOMEOSTASIS THEREWITH
JP2016523517A (ja) 2013-05-02 2016-08-12 イー３エックス バイオ インコーポレイテッド ユビキチンリガーゼのモジュレーターを同定するための方法
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
MD3277677T2 (ro) 2015-03-30 2021-07-31 Mission Therapeutics Ltd Compuși de 1-ciano-pirolidină utilizați ca inhibitori de USP30
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
CN111592534A (zh) 2020-08-28
JP2021138734A (ja) 2021-09-16
CN107001339A (zh) 2017-08-01
KR102493967B1 (ko) 2023-01-31
CA2958262C (en) 2023-02-14
LT3197883T (lt) 2020-07-10
US11472798B2 (en) 2022-10-18
HRP20200962T1 (hr) 2020-10-02
RU2017105296A3 (enExample) 2019-01-22
US10774078B2 (en) 2020-09-15
CA2958262A1 (en) 2016-03-31
US20200369658A1 (en) 2020-11-26
AU2015323572A1 (en) 2017-03-23
RU2017105296A (ru) 2018-10-24
RU2691389C2 (ru) 2019-06-13
JP2019178161A (ja) 2019-10-17
AU2015323572B2 (en) 2019-09-19
US9926307B2 (en) 2018-03-27
ES2798473T3 (es) 2020-12-11
MX2017003358A (es) 2017-09-13
WO2016046530A1 (en) 2016-03-31
JP6549703B2 (ja) 2019-07-24
CN111592534B (zh) 2023-06-30
PL3197883T3 (pl) 2020-10-19
CN107001339B (zh) 2020-03-17
EP3197883A1 (en) 2017-08-02
PT3197883T (pt) 2020-06-22
JP6959299B2 (ja) 2021-11-02
US20170247365A1 (en) 2017-08-31
US10392380B2 (en) 2019-08-27
SMT202000323T1 (it) 2020-07-08
SG11201700847YA (en) 2017-04-27
BR112017005887A2 (pt) 2017-12-12
US20180162852A1 (en) 2018-06-14
US20190330202A1 (en) 2019-10-31
GB201416754D0 (en) 2014-11-05
KR20170055499A (ko) 2017-05-19
HUE050732T2 (hu) 2021-01-28
US11993595B2 (en) 2024-05-28
EP3197883B1 (en) 2020-03-18
DK3197883T3 (da) 2020-06-22
IL250345A0 (en) 2017-03-30
JP7261264B2 (ja) 2023-04-19
CY1122983T1 (el) 2021-10-29
US20230052191A1 (en) 2023-02-16
IL250345B (en) 2019-05-30
RS60468B1 (sr) 2020-07-31
EP3828179A1 (en) 2021-06-02
JP2017530960A (ja) 2017-10-19

Similar Documents

Publication Publication Date Title
IL250345B (en) new compounds
IL250592A0 (en) new compounds
AP2017009836A0 (en) Aminopyridyloxypyrazole compounds
GB201417011D0 (en) Novel compounds
GB201417094D0 (en) Novel compounds
GB201405991D0 (en) Novel compounds
GB201417018D0 (en) Novel compounds
GB201402431D0 (en) Compounds
AP2016009432A0 (en) Novel compounds
GB201406591D0 (en) Compounds
GB201411236D0 (en) Novel compounds
GB201411239D0 (en) Novel compounds
GB201406956D0 (en) Compounds
GB201404987D0 (en) Compounds
GB201404002D0 (en) Novel compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
IL248983A0 (en) new compounds
GB201419102D0 (en) Novel compounds
GB201407695D0 (en) Compounds
GB201405361D0 (en) Compounds
ZA201605726B (en) Novel compounds
GB201421834D0 (en) Novel compounds
GB201421784D0 (en) Novel compounds
GB201417043D0 (en) Novel compounds
GB201417041D0 (en) Novel compounds